Quantbot Technologies LP Decreases Stock Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Quantbot Technologies LP decreased its holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 34.4% in the third quarter, Holdings Channel.com reports. The institutional investor owned 18,323 shares of the company’s stock after selling 9,625 shares during the period. Quantbot Technologies LP’s holdings in GoodRx were worth $127,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. nVerses Capital LLC purchased a new stake in shares of GoodRx during the 3rd quarter valued at about $33,000. Plato Investment Management Ltd purchased a new stake in shares of GoodRx during the 2nd quarter valued at about $43,000. Dark Forest Capital Management LP purchased a new stake in shares of GoodRx during the 2nd quarter valued at about $86,000. Quest Partners LLC purchased a new stake in shares of GoodRx during the 3rd quarter valued at about $160,000. Finally, Deerfield Management Company L.P. Series C purchased a new stake in shares of GoodRx during the 2nd quarter valued at about $173,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Trading Down 3.4 %

GDRX stock opened at $4.90 on Friday. GoodRx Holdings, Inc. has a 1-year low of $4.09 and a 1-year high of $9.26. The company has a debt-to-equity ratio of 0.70, a current ratio of 5.48 and a quick ratio of 5.48. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of -163.33, a PEG ratio of 3.58 and a beta of 1.29. The business has a 50 day simple moving average of $5.83 and a two-hundred day simple moving average of $7.18.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price target on shares of GoodRx in a research report on Friday, August 16th. Citigroup reduced their price target on shares of GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th. Mizuho began coverage on shares of GoodRx in a report on Wednesday. They issued a “neutral” rating and a $5.00 target price for the company. Raymond James raised shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price for the company in a report on Friday, August 9th. Finally, UBS Group reduced their target price on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.60.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.